EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic and immune microenvironment characterization of HER2 ‐positive gastric cancer: Their association with response to trastuzumab‐based treatment

Hyun Jung Kwon, Yujun Park, Soo Kyung Nam, Enoch Kang, Ka-Kyung Kim, Inhae Jeong, Yoonjin Kwak, Jeesun Yoon, Tae-Yong Kim, Keun-Wook Lee, Do-Youn Oh, Seock-Ah Im und 6 weitere

Cancer Medicine · 2023-05 · 12 (9) · 10371-10384

DOI: 10.1002/cam4.5769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023-05. Verfasst von Hyun Jung Kwon und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to determine the molecular and immune microenvironment characteristics of HER2‐positive gastric cancer (GC) related to the patient's response to first‐line trastuzumab‐based treatment.

Methods

Eighty‐three cases of HER2‐positive advanced gastric adenocarcinoma patients treated with trastuzumab were enrolled. Targeted deep sequencing and transcriptome analysis were performed on selected 21 cases (exploration cohort) along with two post‐treatment samples. The results were compared between patients progressed before 6 months (Group 2) and others (Group 1), and were validated by FISH and immunohistochemistry in total cohort. Tumor‐infiltrating immune cells were evaluated using RNA sequencing data and multiplex immunohistochemistry. Progression‐free survival (PFS) analysis was performed.

Results

Group 1 showed frequent amplification of G1/S cell cycle checkpoint‐related genes and upregulated KEGG pathways related to cell proliferation. In contrast, Group 2 had more frequent EGFR, HER3, and MET amplification and higher RNA expression in immune‐related KEGG pathways than Group 1. In total cohort, significant predictors of better PFS were cell cycle‐related including CCNE1 amplification, Cyclin A and PLK1 overexpression, and decreased Cyclin D3 and HER3 expression ( p < 0.05), or immune‐related including high density of CD3 − CD57 + NK cells and PD‐L1 combined positive score ≥5 ( p < 0.05). The best prognostic predictors were a combination of Cyclin A, Cyclin E, p21, and HER3 ( p < 0.001).

Conclusion

HER2‐positive GC with favorable response to trastuzumab were characterized by cell cycle‐related gene alterations and increased CD3 − CD57 + NK cell infiltration. These findings would be helpful to the fine modulation of therapeutic strategies for patients with HER2‐positive GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansTrastuzumabErb-b2 Receptor Tyrosine KinasesPrognosisCell ProliferationTumor Microenvironment

Stichwörter der Autor:innen

HER2-positive gastric cancerNK cellPD-L1cell cycletrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
  • Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
  • Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Macrogen Inc., Seoul, Republic of Korea.

ORCID-Profile: Hyuk-Joon Lee, Hye Seung Lee

Förderung

  • National Research Foundation

Zitieren

APA

Kwon, H. J., Park, Y., Nam, S. K., Kang, E., Kim, K. K., Jeong, I., Kwak, Y., Yoon, J., Kim, T. Y., Lee, K. W., Oh, D. Y., Im, S. A., Kong, S. H., Park, D. J., Lee, H. J., Kim, H. H., Yang, H. K., & Lee, H. S. (2023). Genetic and immune microenvironment characterization of HER2 ‐positive gastric cancer: Their association with response to trastuzumab‐based treatment. Cancer Medicine. https://doi.org/10.1002/cam4.5769

Vancouver

Kwon HJ, Park Y, Nam SK, Kang E, Kim KK, Jeong I, et al. Genetic and immune microenvironment characterization of HER2 ‐positive gastric cancer: Their association with response to trastuzumab‐based treatment. Cancer Medicine. 2023. doi:10.1002/cam4.5769

BibTeX
@article{Kwon2023,
  author = {Kwon, Hyun Jung and Park, Yujun and Nam, Soo Kyung and Kang, Enoch and Kim, Ka-Kyung and Jeong, Inhae and Kwak, Yoonjin and Yoon, Jeesun and Kim, Tae-Yong and Lee, Keun-Wook and Oh, Do-Youn and Im, Seock-Ah and Kong, Seong-Ho and Park, Do Joong and Lee, Hyuk-Joon and Kim, Hyung-Ho and Yang, Han-Kwang and Lee, Hye Seung},
  title = {Genetic and immune microenvironment characterization of HER2 ‐positive gastric cancer: Their association with response to trastuzumab‐based treatment},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5769}
}
Kostenlos starten →